Top Ten most popular articles on this week

pharmafile | February 21, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug market, Europe, coronavirus, opioid crisis, opioids 

The coronavirus is again in the news, with the Indian government considering banning exports of medicine as the epidemic threatens vital pharmaceutical supplies from China. This is not just a regional issue, as Europe and the US are also having their drug production pipeline disrupted by the epidemic. 

In UK news, NICE gives initial ‘no’ to NHS England for kidney cancer drug, while experts have called on the organisation to ban the sale of over the counter codeine. 

10. Global drug market’s production line threatened by coronavirus

The global drug market is facing issues over production due to the coronavirus ravaging the supply line from China.

9. Europe approves first treatment for transthyretin amyloidosis in cardiomyopathy patients: Pfizer’s Vyndaqel

The European Commission (EC) has awarded marketing approval to Pfizer’s Vyndaqel (tafamidis), it has emerged, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult cardiomyopathy patients (ATTR-CM).

8. Experts call on NICE to recommended a ban on OTC codeine sales

Experts have called for a ban on the sale of over the counter codeine as NICE is set to publish its draft guidance for the management of chronic pain next week.

7. Novartis’ Beovu approved in Europe after outclassing Eylea in wet age-related macular degeneration

The European Commission (EC) has chosen to approve Novartis’ Beovu (brolucizumab) injection, it has emerged, as a treatment for wet age-related macular degeneration (AMD).

6. Janssen shows off Phase 3b interim data for Stelara in Crohn’s disease

Janssen has revealed new interim Phase 3b data from a study investigating the efficacy of Stelara (ustekinumab) in the treatment of moderate to severe Crohn’s disease (CD).

5. CEO of PixarBio Corporation sentenced to prison for defrauding investors

Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in prison for defrauding investors and obstructing a federal investigation.

4. GlaxoSmithKline acquires two solid tumor cell therapies from Immatics for $50 million

GlaxoSmithKline has struck a deal to access two Immatics T-cell receptor (TCR) therapeutics.

3. Strong Phase 3 data for Takeda’s subcutaneous Entyvio in moderate to severe Crohn’s disease

Takeda has shared positive new Phase 3 data on a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab) as a maintenance therapy for moderately to severely active Crohn’s disease (CD) in adult patients.

2. India considering export restrictions on antibiotics due to coronavirus

The Indian government is considering an export ban on antibiotics, vitamins and hormones due to the lockdown of Hubei province, the epicenter of the coronavirus and a major supplier of materials for pharmaceutical ingredients.

1. NICE gives initial ‘no’ to NHS England for kidney cancer drug

The National Institute for Health and Care Excellence (NICE) has not recommended Keytruda (pembrolizumab) and Inlyta (axitinib) for the treatment of advanced renal cell cancer.

Related Content

FDA approves prescription nasal spray for opioid overdose treatment

The US Food and Drug Administration (FDA) has announced that it has approved Opvee, the …

EC approves combination treatment for kidney cancer

The European Commission (EC) has approved Ipsen’s Cabometyx in combination with Opdivo as a first-line …

coronavirus’s weekly COVID-19 news round-up

The past week has continued to see positive COVID-19 news; CytoDyn’s treatment for patients with …

Latest content